TruSight Oncology

TruSight Oncology is a set of NGS platform reagents for the detection of cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.Read More...
Select Product(s)

TruSight® Oncology Library Prep

20010184

Price
 
 

TruSight Oncology DNA Library Prep

20010185

Price
 
 

TruSight® Oncology RNA Library Prep

20010186

Price
 
 

TruSight® Oncology Enrichment

20010187

Price
 
 

Product Highlights

The enrichment-based next-generation sequencing (NGS) reagents enable simultaneous analysis of DNA and RNA, and can cover a wide range of cancer variant types. The comprehensive nature of this methodology provides laboratories with a deep view into the genetics of cancer.

  • Accurate Results from Low-Quality Samples1
    Enables variant detection with as little as 40 ng DNA and RNA input, maximizing the results from precious formalin-fixed, paraffin-embedded (FFPE) samples.
  • Supports Comprehensive Coverage of Cancer-Related Variants
    Allows the assessment of multiple variant types in one assay using DNA and RNA which creates efficiencies in sample usage, time, and cost.
  • Integrated, Streamlined Workflow
    DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
  • Flexible Applications
    Enrichment-based workflow allows for a wide variety of content, input types, and applications.

Frequently Purchased Together

Specifications

Method-Specific Workflow Example

 

Feature Article

Genomics Powering Access to the Latest Cancer Breakthroughs

Garret Hampton discusses how TruSight Oncology can be extended to whole-exome and -genome sequencing and sequencing RNA transcripts for profiling of cancers.

Read More

Related Products

TruSight Tumor 170

Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.


TruSight RNA Fusion Panel

Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.


TruSight Oncology 500

Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.


References
  1. Data on file. Illumina, Inc. March 2017.